natgillin/translations-raw huggingface dataset:
The plasma concentrations of olanzapine observed across the dose range of 150mg every 4 weeks to 300mg every 2 weeks illustrate increased systemic olanzapine exposure with increased ZYPADHERA doses.
Plazemske koncentracije olanzapina, ki so jih opazovali v razponu odmerka od 150 mg vsake 4 tedne do 300 mg vsaka 2 tedna, kažejo na povišano sistemsko izpostavljenost olanzapinu pri zvišanih odmerkih zdravila ZYPADHERA.
The plasma concentrations of the major circulating metabolites, M4 and M16, are approximately 23% and 29% that of the parent compound, respectively.
Koncentraciji glavnih presnovkov v plazmi, M4 oziroma M16, sta približno 23 % oziroma 29 % koncentracije izhodne spojine.
The plasma elimination half-life is about 1.3 hours after repeated once-daily dosing.
Plazemski eliminacijski razpolovni čas po večkratnem odmerjanju enkrat na dan okrog 1,3 ure.
The plasma elimination half-life is approximately 2.5 hours for the amifampridine and 4 hours for the 3-N- acetylated amifampridine metabolite.
Razpolovna doba izločanja iz plazme je približno 2,5 uri za amifampridin in 4 ure za presnovek 3-N-acetilirani amifampridin.
The plasma elimination half-life of benazepril hydrochloride and benazeprilat, when dosed with FORTEKOR PLUS tablets is 0.36 h and 8.36 h, respectively.
Po odmerku tablet FORTEKOR PLUS je razpolovni čas izločanja benazeprilijevega klorida iz plazme 0,36 ure in benazeprilata 8,36 ure.
The plasma eltrombopag concentration-time data collected in 88 patients with ITP in Studies TRA100773A and TRA100773B were combined with data from 111 healthy adult subjects in a population PK analysis.
Podatki o koncentraciji eltrombopaga v plazmi v odvisnosti od časa, ki so bili pridobljeni pri 88 bolnikih z ITP v študijah TRA100773A in TRA100773B, so bili združeni s podatki analize populacijske farmakokinetike pri 111 zdravih odraslih osebah.
The plasma exposure at the assumed threshold for tumour development in rats (i.e. the dose where no FAH and liver tumours were detected) was in the same range as the clinical exposure.
Plazemska izpostavitev pri domnevnem pragu za razvoj tumorjev pri podganah (t.j. odmerek pri katerem FAH in tumorji jeter niso bili zaznani) je bila v istem obsegu kot izpostavitev v klinični uporabi.
The plasma half life of axitinib ranges from 2.5 to 6.1 hours.
Razpolovni čas izločanja aksitiniba iz plazme se giblje v razponu od 2,5 do 6,1 ure.
The plasma half-life in adults was 7±1 hours and did not vary either with dose, route of administration or repeated administration.
Plazemski razpolovni čas pri odraslih je 7  1 ura in se ne spreminja z odmerkom, potjo uporabe ali ponavljajočo se uporabo.
The plasma half-life is 30–40 hours.
Njegova razpolovna doba v plazmi je 30-40 ur.
The plasma half-life of dexamethasone is approximately 250 minutes.
Plazemski razpolovni čas deksametazona je približno 250 minut.
The plasma half-life was 1.3–2.7 hours, and the majority of the total radio-activity administered was excreted within 3 days of the last administration.
Razpolovni čas v plazmi je bil 1,3 - 2,7 ure in večina skupne prejete radioaktivnosti je bila izločena v treh dneh od zadnjega odmerka.
The plasma levels in patients with a genetic predisposition for poor function of OATP1B1 transporter are increased and in these patients a higher rate of adverse events, especially with regard to gastrointestinal events, as well as CNS effects might be expected (see section 4.4).
Plazemske koncentracije pri bolnikih z gensko nagnjenostjo k slabemu delovanju prenašalca OATP1B1 so zvišane in pri teh bolnikih se lahko pričakuje več neželenih učinkov, zlasti učinkov na prebavila in osrednje živčevje (glejte poglavje 4.4).
The plasma levels in patients with a genetic predisposition for poor function of OATP1B1 transporter are increased, and in these patients a higher rate of adverse events, especially with regard to gastrointestinal events, as well as CNS effects might be expected (see section 5.2).
Plazemske koncentracije pri bolnikih z gensko nagnjenostjo k slabemu delovanju prenašalca OATP1B1 so zvišane in pri teh bolnikih se lahko pričakuje več neželenih učinkov, zlasti učinkov na prebavila in osrednje živčevje (glejte poglavje 5.2).
The plasma levels of lidocaine and prilocaine in male and female subjects were below the level associated with toxicity (5000 ng/ml).
Ravni lidokaina in prilokaina v plazmi pri moških in ženskih preiskovancih so bile pod ravnjo, povezano s toksičnostjo (5000 ng/ml).
The plasma levels of ritonavir are less than 7% of those obtained after the ritonavir dose of 600 mg twice daily.
Koncentracija ritonavirja v plazmi je bila manj kot 7% tiste, ki je dosežena po odmerjanju ritonavirja 600 mg dvakrat na dan.
The plasma methionine concentrations should be kept below 1000 µM. It is recommended to measure plasma methionine level at start of treatment and about annually or biannually thereafter.
Koncentracija metionina v plazmi mora biti nižja od 1000 µM. Priporočljivo je izmeriti raven metionina na začetku zdravljenja in nato približno enkrat na leto ali enkrat na dve leti.
The plasma PAA to PAGN ratio may be useful in dosage monitoring. (see section 5.2).
Razmerje med plazemsko PAA in PAGN je lahko uporabno pri nadzorovanju odmerjanja. (Glejte Poglavje 5.2)
The plasma pharmacokinetics following intravenous doses (0.3 – 10 μg/kg/24 hr) were also studied.
Proučevana je bila tudi plazemska farmakokinetika po intravenskem odmerku (0,3 - 10 µg/kg/24 ur).
The plasma pharmacokinetics following intravenous doses (0.3 – 10 μg/kg/24 hr) were also studied.
Proučevana je bila tudi plazemska farmakokinetika po intravenskem odmerku (0,3–10 µg/kg/24 ur).
The plasma pharmacokinetics of Caelyx were evaluated in 23 patients with KS who received single doses of 20 mg/m2 administered by a 30-minute infusion.
Plazemsko farmakokinetiko zdravila Caelyx so ovrednotili pri 23 bolnikih s Kaposijevim sarkomom, ki so prejeli po en odmerek 20 mg/m2 v 30-minutni infuziji.
The plasma pharmacokinetics of total irinotecan and total SN-38 were evaluated in patients with cancer who received ONIVYDE, as a single agent or as part of combination chemotherapy, at doses between 60 and 180 mg/m2.
Plazemsko farmakokinetiko skupnega irinotekana in skupnega SN-38 so ocenjevali pri bolnikih z rakom, ki so prejemali zdravilo ONIVYDE samostojno ali kot del kombinirane kemoterapije v odmerkih med 60 in 180 mg/m2.
The plasma protein binding is low, with the unbound fraction ranging from 60% at 2 ng/ml to 77% at 2000 ng/ml of zoledronic acid.
Vezava na beljakovine v plazmi je majhna, tako da nevezana frakcija predstavlja od 60 % pri koncentraciji zoledronske kisline 2 ng/ml do 77 % pri koncentraciji 2.000 ng/ml..
The plasma protein binding of 14C-abiraterone in human plasma is 99.8%.
Pri ljudeh se 14C-abirateron veže na beljakovine v plazmi v 99,8%.
The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses.
Delež vezave febuksostata na plazemske beljakovine je približno 99,2 %, (primarno na albumin) in je enak pri koncentracijah, doseženih z odmerki 80 mg in 120 mg.
The plasma protein binding of fentanyl is 80 – 85 %.
80–85 % fentanila se veže na plazemske beljakovine.
The plasma protein binding of fentanyl is approximately 80.
Delež vezave fentanila na plazemske proteine znaša približno 80 %.
The plasma protein binding of non-liposomal irinotecan is moderate (30% to 68%), and SN-38 is highly bound to human plasma proteins (approximately 95%).
Vezava neliposomskega irinotekana na plazemske beljakovine je zmerna (30 – 68-odstotna), SN-38 pa se močno veže na plazemske beljakovine (približno 95- odstotno).
The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1,000 ng/ml.
Vezava olanzapina na plazemske beljakovine je bila okoli 93 % v razponu koncentracij od približno 7 do približno 1000 ng/ml.
The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1000 ng/ml.
Vezava olanzapina na plazemske je bila okoli 93 % v razponu konentracij od približno 7 do približno 1000 ng/ml.
The plasma protein binding of ONIVYDE is negligible (< 0.44% of total irinotecan in ONIVYDE).
Vezava zdravila ONIVYDE na plazemske beljakovine je zanemarljiva (< 0,44 % skupnega irinotekana v zdravilu ONIVYDE).
The plasma protein binding of the (+)-(R) and (-)-(S) enantiomers was found to be 55% and 65% respectively.
Vezava na plazemske proteine (+)-(R) enantiomerov je znašala 55 % in (-)-(S) enantiomerov 65 %.
The plasma protein binding of voriconazole was similar in subjects with different degrees of renal impairment. (see sections 4.2 and 4.4).
Vezava vorikonazola na beljakovine v plazmi je bila pri preiskovancih z različno izrazito ledvično okvaro podobna (glejte poglavji 4.2 in 4.4).
The plastic bottle adapter (in the medicine pack)
nastavek za plastično steklenico (v pakiranju) vodo.
The plastic bottle adapter (in the medicine pack)
nastavek za plastično steklenico (v pakiranju), vodo.
The plastic bottle comes with a child resistant cap and must be opened as follows:
Plastenka ima za otroke varno zaporko, ki jo lahko odprete takole:
The plastic bottle comes with a child resistant cap and must be opened as follows:
Plastenka ima za otroke varno zaporko, ki jo odprete takole:
The plastic bottle comes with a child resistant cap and should be opened as follows:
Plastenka ima za otroke varno zaporko, ki jo lahko odprete na naslednji način:
The plastic bottle comes with a child resistant cap and should be opened as follows:
Plastenka ima za otroke varno zaporko, ki jo lahko odprete, kot sledi:
The plastic needle cover will “pop” off.
Plastični pokrovček igle se bo odlomil.
The platelet count will increase within 4 days of stopping treatment with anagrelide and will return to pre-treatment levels within 10 to 14 days.
Število krvnih ploščic bo v štirih dneh po prenehanju zdravljenja z anagrelidom naraslo, po 10 do 14 dneh pa se bo vrnilo na raven pred zdravljenjem.
The platelet counts of ITP patients who received weekly doses of 1 or 3 µg/kg of romiplostim were within the range of 50 to 450 x 109/l for most patients.
Pri večini bolnikov z ITP, ki so prejeli 6 tedenskih odmerkov 1 ali 3 µg/kg romiplostima, je bilo število trombocitov 50 do 450 x 109/l.
The PLATO [PLATelet Inhibition and Patient Outcomes] study, a comparison of ticagrelor to clopidogrel, both given in combination with ASA and other standard therapy.
Študije PLATO [PLATelet Inhibition and Patient Outcomes], ki je primerjala ticagrelor in klopidogrel, oba v kombinaciji z ASA in drugim standardnim zdravljenjem.
The Plegridy Initiation Pack contains 1x 63 micrograms pre-filled syringe (orange labelled syringe, 1st dose) and 1x 94 micrograms pre-filled syringe (blue labelled syringe, 2nd dose) in sealed plastic trays.
Začetno pakiranje zdravila Plegridy vsebuje 1 x 63-mikrogramsko napolnjeno injekcijsko brizgo (brizga z oranžno nalepko, 1. odmerek) in 1 x 94-mikrogramsko napolnjeno injekcijsko brizgo (brizga z modro nalepko, 2. odmerek) na zatesnjenem plastičnem pladnju.
The Plegridy Initiation Pack contains one orange pre-filled pen of 63 micrograms and one blue pre-filled pen of 94 micrograms.
Začetno pakiranje zdravila Plegridy vsebuje en oranžen napolnjen injekcijski peresnik s 63 mikrogrami in en moder napolnjen injekcijski peresnik s 94 mikrogrami.
The Plegridy Initiation Pack contains one orange pre-filled syringe of 63 micrograms and one blue pre-filled syringe of 94 micrograms.
Začetno pakiranje zdravila Plegridy vsebuje eno oranžno napolnjeno injekcijsko brizgo s 63 mikrogrami in eno modro napolnjeno injekcijsko brizgo s 94 mikrogrami.
The Plegridy Pen Initiation Pack contains 1x 63 micrograms pre-filled pen (orange labelled pen, 1st dose) and 1x 94 micrograms pre-filled pen (blue labelled pen, 2nd dose) in a protective plastic tray.
Začetno pakiranje z napolnjenim injekcijskim peresnikom zdravila Plegridy vsebuje 1 x 63-mikrogramski napolnjen injekcijski peresnik (brizga z oranžno nalepko, 1. odmerek) in 1 x 94-mikrogramski napolnjen injekcijski peresnik (brizga z modro nalepko, 2. odmerek) na zaščitnem plastičnem pladnju.
The Plegridy pen is ready to inject after the cap is removed.
Injekcijski peresnik zdravila Plegridy je pripravljen na injiciranje, ko odstranite pokrovček.
The plunger goes in first.
Vložek vstavite z batom obrnjenim naprej.
The plunger only moves a little with each  injection and you may not notice that it moves.
Bat se pri vsakem injiciranju premakne le malo, morda premikanja sploh ne boste opazili.
The plunger only moves a little with each injection and you may not notice that it moves.
Bat se pri vsakem injiciranju premakne le malo, morda premikanja sploh ne boste opazili.
The plunger only moves a little with each injection and you may not notice that it moves.
premakne in morda ne boste opazili, da se premika.
The plunger only moves a little with each injection, and you may not notice that it moves.
Bat se pri vsakem injiciranju le rahlo premakne in morda premikanja sploh ne boste opazili.
The plunger rod MUST NOT be drawn back to rinse the pre-filled syringe, in order to avoid contamination and to ensure that the correct volume is ejected.
Bata NE SMETE potegniti nazaj zaradi spiranja napolnjene injekcijske brizge, da preprečite kontaminacijo in zagotovite vbrizganje pravilnega volumna.
The plunger will reach the end of the cartridge when the total of 300 units of insulin has been used.
Bat bo vložku dosegel konec, ko bo porabljenih vseh 300 enot insulina.
The plunger will reach the end of the cartridge when the total of 300 units of insulin has been used.
Ko porabite vseh 300 enot insulina, bat doseže konec vložka.
The plunger will reach the end of the cartridge when the total of 300 units of insulin have been used.
Ko porabite vseh 300 enot insulina, bat doseže konec vložka.
The point estimate for incidence of Major VTE and VTE related mortality for the 150 mg dose was slightly worse than enoxaparin (table 10).
Točkovna ocena pogostnosti večjih trombemboličnih dogodkov in umrljivosti v povezavi s trombemboličnim dogodkom je bila za odmerek 150 mg nekoliko slabša kot pri enoksaparinu (preglednica 10).
The point estimate for incidence of major VTE and VTE related mortality for the 150 mg dose was slightly worse than enoxaparin (table 6).
Točkovna ocena pogostnosti večjih trombemboličnih dogodkov in umrljivosti v povezavi s trombemboličnim dogodkom je bila za odmerek 150 mg nekoliko slabša kot pri enoksaparinu (preglednica 6).
The point estimate of the hazard ratio (HR) was 0.461 (95% confidence interval, 0.242-0.879) in the full population.
Ocenjena vrednost razmerja ogroženosti (RO) je bila 0,461 (95-% interval zaupanja, 0,242–0,879) pri celotni poulaciji.
The polypropylene flip off cap should be removed to expose the central portions of the rubber stopper.
Dvižno zaporko iz polipropilena je treba odstraniti, tako da se pokaže osrednji del gumijastega zamaška.
The polysaccharides are chemically attached (conjugated) to tetanus toxoid as a carrier protein because this improves the response to the vaccine.
Polisaharidi so na tetanusov toksoid kemično vezani (konjugirani) kot nosilna beljakovina, ker se tako izboljša odziv na cepivo.
The pooled ABSSSI Phase 3 clinical trials included 976 adult patients who were treated with a single 1,200 mg dose of oritavancin.
Združena klinična preskušanja ABSSSI faze 3 so vključevala 976 odraslih bolnikov, zdravljenih z enim 1.200 mg odmerkom oritavancina.
The pooled analysis of these two studies showed Duaklir Genuair to be associated with statistically significantly greater improvements in TDI focal score compared to aclidinium (0.4 units, p=0.016) or formoterol (0.5 units, p=0.009).
V zbirni analizi učinkovitosti teh dveh študij je zdravilo Duaklir Genuair pokazalo povezavo s statistično značilnim izboljšanjem skupne ocene indeksa TDI v primerjavi z aklidinijem (0,4 enote, p = 0,016) ali formoterolom (0,5 enote, p = 0,009).
The pooled analysis of trials using the Arizona Sexual Experience Scale (ASEX) showed that Thymanax was not associated with sexual dysfunction.
Zbirna analiza preskušanj z arizonsko lestvico spolne izkušnje (ASEX – Arizona Sexual Experience Scale) je pokazala, da zdravilo Thymanax ni povezano s spolno disfunkcijo.
The pooled analysis of trials using the Arizona Sexual Experience Scale (ASEX) showed that Valdoxan was not associated with sexual dysfunction.
Zbirna analiza preskušanj z arizonsko lestvico spolne izkušnje (ASEX – Arizona Sexual Experience Scale) je pokazala, da zdravilo Valdoxan ni povezano s spolno disfunkcijo.
The pooled data from the Phase 3 TMC278-C209 and TMC278-C215 studies of treatment-naïve patients also demonstrate that serum creatinine increased and estimated glomerular filtration rate (eGFR) decreased over 96 weeks of treatment with rilpivirine.
Združeni podatki iz študij faze III TMC278-C209 in TMC278-C215, za predhodno nezdravljene bolnike, kažejo tudi na povečanje serumskega kreatinina in zmanjšanje ocenjene hitrosti glomerularne filtracije (eGFR-estimated glomerular filtration rate) v 96 tednih zdravljenja z rilpivirinom.
The PopPK model-based mean (CV %) clearance for olaratumab was 0.56 L/day (33 %).
Povprečen (CV %) očistek olaratumaba, ocenjen z modelom PopFK, je bil 0,56 l/dan (33 %).
The population enrolled mainly consisted in children with mild to moderate hepatitis C. Sustained virological response rates in children and adolescents
Populacija je vključevalapredvsem otroke z blagim do zmernim hepatitisom C. Delež trajenega virološkega odziva pri otrocih in mladostnikih je bil podoben tistemu pri odraslih.
The population estimate for the absorption rate constant Ka was 2.08 hr-1 (standard deviation of random effect = 122%).
Populacijska ocena za konstanto hitrosti absorpcije Ka je bila 2,08 ur -1 (standardna deviacija naključnega učinka = 122
The population included 164 patients (perampanel N=82, placebo N=82).
Populacija je zajemala 164 bolnikov (n = 82 za perampanel in n = 82 za placebo).
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics.
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starost ≥60 let (26 % ≥70 let ) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
The population included in the influenza treatment studies is comprised of otherwise healthy adults/adolescents and patients “at risk” (patients at higher risk of developing complications associated with influenza, e.g. older people and patients with chronic cardiac or respiratory disease).
Populacijo, vključeno v študije zdravljenja gripe, sestavljajo drugače zdravi odrasli/mladostniki in “ogroženi’’ bolniki (bolniki z večjim tveganjem za razvoj zapletov, povezanih z gripo, npr. starejši ljudje in bolniki s kronično srčno ali respiratorno boleznijo).
The population pharmacokinetic (PopPK) model-based mean (CV %) volume of distribution of olaratumab at steady state (Vss) was 7.7 L (16 %).
Povprečna (CV %) prostornina porazdelitve olaratumaba v stanju dinamičnega ravnovesja (Vss), ocenjena z modelom populacijske farmakokinetike (PopFK), je bila 7,7 l (16 %).
The population pharmacokinetic analysis suggest that Asians have 56% lower total irinotecan average steady state concentration (3.93 [95%CI: 3.68-4.2] and 1.74 [95%CI: 1.58-1.93] mg/l, respectively) and 8% higher total SN-38 average steady state concentration (0.97 [95%CI: 0.92-1.03] and 1.05 [95%CI: 0.98-1.11] ng/ml, respectively) than Caucasians.
Populacijska farmakokinetična analiza kaže, da imajo osebe azijskega porekla za 56 % nižje povprečne koncentracije skupnega irinotekana v dinamičnem ravnovesju (3,93 [95-odstotni IZ: 3,68 – 4,2] oziroma 1,74 [95-odstotni IZ: 1,58 – 1,93] mg/l) in za 8 % višje povprečne koncentracije skupnega SN-38 v dinamičnem ravnovesju (0,97 [95-odstotni IZ: 0,92 – 1,03] oziroma 1,05 [95- odstotni IZ: 0,98 – 1,11] ng/ml) kot belci.
The population pharmacokinetic analysis using the data from these studies indicated that baseline total bilirubin or AST levels, did not have a clinically meaningful effect on the pharmacokinetics of crizotinib.
Populacijska farmakokinetična analiza podatkov iz teh študij je pokazala, da vrednosti skupnega bilirubina ali AST na začetku zdravljenja niso imele klinično pomembnega vpliva na farmakokinetiko krizotiniba.
The population pharmacokinetics were analysed to evaluate the effects of demographic characteristics.
Vpliv demografskih značilnosti na farmakokinetiko so proučili z analizo populacijske farmakokinetike.
The population PK analysis included 223 patients receiving DARZALEX in two clinical trials (150 subjects received 16 mg/kg).
Analiza populacijske farmakokinetike je vključevala 223 bolnikov, ki so prejemali zdravilo DARZALEX v dveh kliničnih študijah (150 bolnikov je prejemalo odmerek 16 mg/kg).
The population PK analysis on the limited decitabine data indicated no significant PK parameter dependencies on normalized creatinine clearance, an indicator of renal function.
Rezultati analize populacijske farmakokinetike na omejenem obsegu podatkov kažejo, da farmakokinetični parametri niso v večji meri odvisni od normaliziranega očistka kreatinina kot kazalca ledvične funkcije.
The population PK analysis suggested that the following factors had no clinically important effect on the clearance of elotuzumab: age (37 to 88 years), gender, race, baseline LDH, albumin, renal impairment, and mild hepatic impairment.
Analiza populacijske farmakokinetike kaže, da naslednji dejavniki nimajo klinično pomembnega vpliva na očistek elotuzumaba: starost (od 37 do 88 let), spol, rasa, izhodiščna vrednost LDH, albumin, okvara ledvic in blaga okvara jeter.
The population predicted PK exposure parameter values (median with 5th - 95th Percentiles) for Herceptin SC dosing regimens in EBC patients are shown in Table 13 below.
Vrednosti farmakokinetičnih parametrov izpostavljenosti, predvidenih za populacijo (mediana s 5.–95. percentilom), za režim odmerjanja zdravila Herceptin v subkutani obliki pri bolnikih z zgodnjim rakom dojk so prikazani v spodnji preglednici 13.
The population predicted PK exposure values (median with 5th - 95th Percentiles) and PK parameter values at clinically relevant concentrations (Cmax and Cmin) for MBC, EBC and AGC patients treated with the approved q1w and q3w dosing regimens are shown in Table 14 (Cycle 1), Table 15 (steady- state), and Table 16 (PK parameters).
Farmakokinetične vrednosti izpostavljenosti, predvidene za populacijo (mediana s 5.–95. percentilom), in vrednosti farmakokinetičnih parametrov pri klinično pomembnih koncentracijah (Cmax in Cmin) za bolnike z MBC, EBC in AGC, zdravljene z odobrenim tedenskim in 3-tedenskim režimom odmerjanja, so prikazane v preglednici 14 (cikel 1), preglednici 15 (stanje dinamičnega ravnovesja) in preglednici 16 (farmakokinetični parametri).
The portion of 13CO2 in the breath samples is determined by isotope-ratio-mass-spectrometry (IRMS) and stated as an absolute difference (-value) between the 00-minute- and the 30-minute-values.
13CO2 v izdihanem zraku je določen s spektrometrično metodo določanja razmerja mase izotopov (IRMS, isotope ratio mass spectrometry) in predstavljen kot absolutna razlika (vrednost Δδ) med 00-minutnimi in 30-minutnimi vrednostmi.
The portion of 13CO2 in the breath samples is determined by isotope-ratio-mass-spectrometry (IRMS) and stated as an absolute difference (-value) between the 00-minute- and the 30-minute-values.
Delež 13CO2 v izdihanem zraku je določen s spektrometrično metodo določanja razmerja mase izotopov (IRMS, isotope ratio mass spectrometry) in predstavljen kot absolutna razlika (vrednost Δδ) med 00-minutnimi in 30-minutnimi vrednostmi.
The portion of 13CO2 in the breath samples is determined by non-dispersive infrared spectrometry and stated as an absolute difference (-value) between the 00-minute- and the 30-minute-values.
13CO2 v izdihanem zraku je določen z nedisperzivno infrardečo spektrometrijo (NDIR, non-dispersive infrared spectrometry) in predstavljen kot absolutna razlika (vrednost Δδ) med 00-minutnimi in 30- minutnimi vrednostmi.